Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years

• Published in: Nephrology, dialysis, transplantation Vol. 20; no. suppl-3; pp. iii3 - iii24
• Main Authors: Jacobs, Claude, Frei, Dieter, Perkins, Alan C.
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.05.2005; Oxford Publishing Limited (England)
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; anaemia; Anemia - blood; Anemia - drug therapy; Anemia - etiology; chronic kidney disease; dialysis; epoetin; Epoetin Alfa; erythropoietin; Erythropoietin - pharmacology; Erythropoietin - therapeutic use; Europe; Female; Health Surveys; Hematinics - pharmacology; Hematinics - therapeutic use; Hemoglobins - analysis; Hemoglobins - drug effects; Humans; iron status; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - therapy; Male; Middle Aged; Recombinant Proteins; Renal Dialysis; Retrospective Studies; Europe
• ISSN: 0931-0509; 1460-2385
• DOI: 10.1093/ndt/gfh1074

The European Survey of Anaemia Management 2003 (ESAM 2003) was a 1 day randomized survey conducted to assess anaemia management in dialysis patients 4 years after the introduction of the European Best Practice Guidelines. The survey included 8100 patients from 11 European countries and Israel. Overall, haemoglobin (Hb) levels ≥11.0 g/dl, as recommended by the guidelines, were achieved in 66% of patients. Only 48% of patients had adequate iron status, with transferrin saturation values missing for 27% and functional or absolute iron deficiency reported for 17 and 9%, respectively. In order to identify factors affecting epoetin dose and Hb levels, the countries were divided into two groups based on the percentage of patients with Hb levels ≥11.0 g/dl (>70% in group 1 and 60–70% in group 2). The most probable causes for better management in group 1 were administration of higher epoetin doses and better monitoring and management of iron status. In patients with Hb <11.0 g/dl, mean epoetin-α/β doses were significantly lower for subcutaneous than intravenous (i.v.) administration, whereas mean doses were similar for both routes in patients with Hb ≥11.0 g/dl. When standardized for Hb levels, the dose ratio of i.v. epoetin-α/β to i.v. darbepoetin alfa was 176:1 (95% confidence interval, 166:1–189:1). Limited comparisons between the eight countries that participated in ESAM 2003 and the original ESAM revealed that many patients still have haemoglobin levels below the current recommendations despite significant improvements in management of renal anaemia over the last 5 years.